Technical Analysis for IPCI - Intellipharmaceutics International Inc.

Grade Last Price % Change Price Change
grade F 0.3001 1.73% 0.01
IPCI closed up 3.51 percent on Thursday, January 17, 2019, on 19 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Up
See historical IPCI trend table...

Date Alert Name Type % Chg
Jan 17 20 DMA Support Bullish 1.73%
Jan 17 Wide Bands Range Expansion 1.73%
Jan 16 Upper Bollinger Band Walk Strength 5.30%
Jan 16 Wide Bands Range Expansion 5.30%
Jan 15 Upper Bollinger Band Walk Strength 0.03%
Jan 15 Wide Bands Range Expansion 0.03%
Jan 15 Upper Bollinger Band Touch Strength 0.03%
Jan 14 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -10.42%
Jan 14 Pocket Pivot Bullish Swing Setup -10.42%
Jan 14 NR7 Range Contraction -10.42%

Older signals for IPCI ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Intellipharmaceutics International Inc. engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. It has a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, and pain. The company's products under FDA review include Focalin XR, an extended release capsule for hyperactivity disorder; Effexor XR, an extended release capsule for depression; Protonix, a tablet for gastroesophageal reflux disease; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, bipolar disorder, and depressive disorder; Lamictal XR, a tablet for anti-convulsant for epilepsy; and Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy, as well as product filed with the FDA comprise Pristiq, a tablet for depression. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. for the development and commercialization of generic Focalin XR. Its late stage development product includes Coreg CR, a capsule for heart failure and hypertension; and phase I clinical trial products include Lyrica, a capsule for Neuropathic pain and Oxycodone Hydrochloride, a controlled release capsule for pain. The company's non-generic products under development include Rexista, an oral formulation for pain relief, and Pregabalin, an extended release capsule for neuropathic pain. The company was founded in 1998 and is based in Toronto, Canada.
Is IPCI a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.8
52 Week Low 0.2
Average Volume 1,368,556
200-Day Moving Average 2.6602
50-Day Moving Average 0.3454
20-Day Moving Average 0.2712
10-Day Moving Average 0.2954
Average True Range 0.0467
ADX 16.55
+DI 23.6443
-DI 23.4893
Chandelier Exit (Long, 3 ATRs ) 0.2199
Chandelier Exit (Short, 3 ATRs ) 0.3441
Upper Bollinger Band 0.3315
Lower Bollinger Band 0.2109
Percent B (%b) 0.7
BandWidth 44.469027
MACD Line -0.0167
MACD Signal Line -0.0325
MACD Histogram 0.0158
Fundamentals Value
Market Cap 9.17 Million
Num Shares 31.1 Million
EPS -0.34
Price-to-Earnings (P/E) Ratio -0.87
Price-to-Sales 5.78
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.38
Resistance 3 (R3) 0.37 0.34 0.37
Resistance 2 (R2) 0.34 0.32 0.34 0.36
Resistance 1 (R1) 0.32 0.31 0.33 0.32 0.36
Pivot Point 0.28 0.28 0.29 0.29 0.28
Support 1 (S1) 0.26 0.26 0.27 0.27 0.23
Support 2 (S2) 0.23 0.25 0.23 0.23
Support 3 (S3) 0.21 0.23 0.23
Support 4 (S4) 0.21